CCL11 and triple-A syndrome: CCL11 has an increased expression in cerebral aneurysms and abdominal aortic aneurysms (AAA), which indicates the potential usage as a biomarker in AAA and a possible therapeutic target for the prevention of aneurysm formation and rupture [37, 38].